Topic
Diabetes management
About: Diabetes management is a research topic. Over the lifetime, 6060 publications have been published within this topic receiving 164670 citations.
Papers published on a yearly basis
Papers
More filters
•
28 Feb 2008
TL;DR: In this article, a diabetes management system consisting of a glucose monitoring system, a pump system, and a remote device is presented, where the remote device has a small and durable form factor that can be worn or carried in various ways.
Abstract: In one embodiment, a diabetes management system comprises a glucose monitoring system, a pump system, and a remote device. The glucose monitoring system and pump system are attached to a patient and covered by a soft shell. The glucose monitoring system and the pump system are controlled by the small, touch-screen remote device such a patient can discreetly monitor blood glucose levels and administer insulin dosages. The remote device has a small and durable form factor that can be worn or carried in various ways.
66 citations
••
TL;DR: In this paper, the authors investigated whether the gain in the knowledge of the targets of diabetes care after receiving diabetes self-management education (DSME) predicts the achievement of target A1C levels at 6 months.
Abstract: Optimal glycemic, lipid, and blood pressure control has been shown to decrease the microvascular and macrovascular complications of diabetes (1–10). However, the status of control of these cardiovascular risk factors in individuals with diabetes is far from optimal (11,12). Lack of patients' knowledge of the targets of diabetes care might be one of the reasons for the low level of control of risk factors. Some studies showed that only 23–25% of individuals with diabetes know what the target A1C level is (<7%), and about the same percent of patients know how to interpret A1C values in relation to their own glycemic control (13,14). Improving patients' knowledge might help attain the goals of diabetes management, but the supporting studies are limited (14–18).
We investigated whether the gain in the knowledge of the targets of diabetes care after receiving diabetes self-management education (DSME) predicts the achievement of target A1C levels (<7%) at 6 months.
This is a retrospective study of adult diabetic subjects who received DSME in the American Diabetes Association–certified Diabetes Center of John H. Stroger, Jr. Hospital of Cook County between 2001 and 2004.
Patients with baseline A1C levels ≥7% measured within 1 month of receiving DSME and with an ∼6-month follow-up A1C measurement (ranging 3–12 months and at least 3 months from the baseline A1C) were selected for this study. A1C was measured by the high-performance liquid chromatography method throughout the study period. After the educational sessions, patients received follow-up medical care by endocrinologists in conjunction with their primary …
66 citations
••
TL;DR: To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day‐and‐night hybrid closed‐loop insulin delivery, a large number of families opted for the day-and-night approach.
Abstract: Objective To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day-and-night hybrid closed-loop insulin delivery. Methods Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed-loop experience survey following two 3-week periods of unrestricted day-and-night hybrid closed-loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed-loop technology were explored. Results Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed-loop. Ninety percent of the responders felt less worried about their child's glucose control using closed-loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets. Conclusions Parents/caregivers of very young children reported important quality of life benefits associated with using closed-loop, supporting adoption of this technology in this population.
66 citations
••
TL;DR: The Global Partnership for Effective Diabetes Management as mentioned in this paper provides practical recommendations to help improve the care of patients with type 1 diabetes, including reaching glycaemic goals, overcoming the reality and fear of hypoglycaemia, and appropriate insulin therapy and dose adjustment.
Abstract: The Diabetes Control and Complications Trial (DCCT) led to considerable improvements in the management of type 1 diabetes, with the wider adoption of intensive insulin therapy to reduce the risk of complications. However, a large gap between evidence and practice remains, as recently shown by the Pittsburgh Epidemiology of Diabetes Complications (EDC) study, in which 30-year rates of microvascular complications in the 'real world' EDC patients were twice that of DCCT patients who received intensive insulin therapy. This gap may be attributed to the many challenges that patients and practitioners face in the day-to-day management of the disease. These barriers include reaching glycaemic goals, overcoming the reality and fear of hypoglycaemia, and appropriate insulin therapy and dose adjustment. As practitioners, the question remains: how do we help patients with type 1 diabetes manage glycaemia while overcoming barriers? In this article, the Global Partnership for Effective Diabetes Management provides practical recommendations to help improve the care of patients with type 1 diabetes.
66 citations
••
TL;DR: Novel therapeutic options that hold particular promise for type 2 diabetes management are examined, including early initiation of combination therapy using multiple drugs with different mechanisms of action.
Abstract: In Brief Impaired insulin secretion, increased hepatic glucose production, and decreased peripheral glucose utilization are the core defects responsible for the development and progression of type 2 diabetes. However, the pathophysiology of this disease also includes adipocyte insulin resistance (increased lipolysis), reduced incretin secretion/sensitivity, increased glucagon secretion, enhanced renal glucose reabsorption, and brain insulin resistance/neurotransmitter dysfunction. Although current diabetes management focuses on lowering blood glucose, the goal of therapy should be to delay disease progression and eventual treatment failure. Recent innovative treatment approaches target the multiple pathophysiological defects present in type 2 diabetes. Optimal management should include early initiation of combination therapy using multiple drugs with different mechanisms of action. This review examines novel therapeutic options that hold particular promise.
66 citations